Phase 2b Open-Label Repeat Kidney Biopsy Study
Active, not recruiting · Phase 2 · NCT06740526
Conditions: IgA Nephropathy
At a glance
- Research payments reported, 2025
- $605,407
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 56
About the trial
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Tested
- Sibeprenlimab (drug)
- Dates
- Started 2024-12-05; completion 2028-12-28
- Results posted
- Not yet
Assess impact of sibeprenlimab on IgA deposition and other histological endpoints in kidney tissue at Week 52 relative to baseline
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Otsuka Pharmaceutical Development & Commercialization, Inc. reported $605,407 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dana Rizk Nephrology (Kidney) · Birmingham, AL
- Laura A. Kooienga, MD Nephrology (Kidney) · Denver, CO
- Ashar Luqman, M.D. Nephrology (Kidney) · Sioux City, IA
- Meghan E. Sise, M.D. Nephrology (Kidney) · Boston, MA
- Biruh Workeneh, MD Nephrology (Kidney) · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Denver Nephrologists PC $222,582
- Massachusetts General Hospital, MA $179,527
- Dunes Clinical Research LLC $130,153
- Prolato Research LLC $55,670
- University of Alabama Hospital, AL $17,476
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.